Breaking News, Collaborations & Alliances

Midatech, Janssen Expand Bio-delivery Research Alliance

Midatech to apply Q-Sphera technology to another Janssen experimental molecule to maximize drug loading and optimize in vitro duration of release.

By: Kristin Brooks

Managing Editor, Contract Pharma

Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, extended its existing R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally formed in July 2020.
 
In June 2021, using its Q-Sphera technology, the company successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity. Midatech believes no other organization has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling.
Following the initial program (MTX213), the collaboration has been extended to include another large molecule to the research performed by Midatech for Janssen. The work will concentrate on maximizing drug loading and optimizing in vitro duration of release for this undisclosed Janssen experimental molecule using the Midatech’s Q-Sphera technology.
 
Dmitry Zamoryakhin, Chief Scientific Officer of Midatech, said, “We look forward to working with Janssen and the application of our technology specific to this new API.”
 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters